STRO-4 Antibody for Cross-Species Mesenchymal Cell Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack specific reagents to isolate and characterize multipotential cells in ovine tissues, limiting the therapeutic potential of these cells in pre-clinical and clinical trials, particularly due to the lack of cross-reactive markers between human and ovine species.
Innovation Solution
A novel monoclonal antibody, STRO-4, is generated that specifically binds to heat shock protein-90 beta (HSP-90beta), enabling the identification and isolation of multipotential cells from both human and ovine bone marrow by targeting a unique epitope on HSP-90beta, allowing for the enrichment and characterization of these cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional markers (STRO-1, CD106, CD146) are used for isolating multipotential cells, then human cell isolation is achieved, but cross-reactivity with ovine cells is lost
Solution Approach 1:
The STRO-4 monoclonal antibody was developed to recognize HSP-90beta, a protein that is evolutionarily conserved between human and ovine species. This allows the same antibody to function as a specific marker for multipotential cells in both human and ovine bone marrow, achieving cross-reactivity while maintaining identification precision through targeted binding to the conserved epitope on HSP-90beta
2Measurement precision
If species-specific markers are used for ovine cell isolation, then ovine cell specificity is improved, but applicability to human models is reduced
Solution Approach 1:
By targeting HSP-90beta, a highly conserved heat shock protein present in both human and ovine multipotential cells, the STRO-4 antibody serves as a universal marker that enables precise identification and isolation of ovine cells while simultaneously allowing comparison and application in human cell models, thus achieving both species-specific precision and cross-species versatility
3Ease of manufacture
If non-specific reagents are used for cell isolation, then isolation process is simplified, but cell purity and functional characterization are reduced
Solution Approach 1:
The STRO-4 monoclonal antibody serves as a highly specific intermediary reagent that binds with high affinity to HSP-90beta on the surface of multipotential cells. This specific binding enables precise isolation of pure multipotential cell populations from bone marrow through flow cytometry or magnetic sorting, ensuring both process feasibility and high cell purity with retained functional capabilities for differentiation into osteoblasts, chondrocytes, and adipocytes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The STRO-4 antibody effectively isolates clonogenic multipotential cells, demonstrating high proliferative potential and multi-lineage differentiation capabilities, facilitating the use of ovine models in pre-clinical trials and potentially improving the safety and efficacy of stem cell therapies.
Implementation Method 1
a novel monoclonal antibody (mAb), designated STRO-4 that identifies and isolates multipotential cells from unfractionated ovine and human bone marrow... the STRO-4 antibody is able to isolate essentially all of the clonogenic multipotential cells... the heat shock protein-90 beta (HSP-90beta) protein is expressed on the cell surface of multipotential cells in vivo and monoclonal antibody STRO-4 was found to identify a unique epitope expressed on HSP-90beta
Data Source
Figure 1A~1D
Figure 2A~2C
Figure 3A~3F
AI summary
The present invention relates to a monoclonal antibody designated STRO-4 which specifically binds human and ovine HSP-90beta and its use for enriching multipotential cells such a mesenchymal precursor cells (MPCs).